Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the combination of two established anti-cancer
therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
Specifically, investigators want to determine if the combination of Cetuximab and nivolumab
can help people with advanced cases of HNSCC. Both cetuximab and nivolumab have been used
separately to treat HNSCC and are Food and Drug Administration (FDA) approved in this type of
cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company James and Esther King Biomedical Research Program